Introduction to Cardiovascular Disease
Cardiovascular disease refers to a group of disorders affecting the heart and blood vessels. Furthermore, heart attacks and strokes are among the most common cardiovascular conditions worldwide. These events often occur when blood flow to the heart or brain is blocked by fatty deposits or blood clots. In some cases, strokes may also result from bleeding within the brain.
Types of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels. They include:
–coronary heart disease – a disease of the blood vessels supplying the heart muscle;
–cerebrovascular disease – a disease of the blood vessels supplying the brain;
–peripheral arterial disease – a disease of blood vessels supplying the arms and legs;
–rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria;
–congenital heart disease – birth defects that affect the normal development and functioning of the heart caused by malformations of the heart structure from birth;
–deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs.
Risk Factors for Cardiovascular Disease
The most important behavioural risk factors of cardiovascular disease include unhealthy diet, physical inactivity, tobacco use, and harmful alcohol consumption. Furthermore, these factors can contribute to elevated blood pressure, blood glucose, blood lipids, overweight, and obesity.As a result, individuals may face an increased risk of heart attack, stroke, heart failure, and other cardiovascular complications.These “intermediate risks factors” can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.
Moreover, there are several underlying determinants of cardiovascular diseases that contribute to long-term health risks. These are a reflection of the major forces driving social, economic and cultural change – globalization, urbanization and population ageing. Other determinants of CVDs include poverty, stress and hereditary factors.
In addition, drug treatment of hypertension, diabetes and high blood lipids are necessary to reduce cardiovascular risk and prevent heart attacks and strokes among people with these conditions.
Prevention and Management of Cardiovascular Disease
The key to cardiovascular disease reduction lies in the inclusion of cardiovascular disease management interventions in universal health coverage packages, although in a high number of countries health systems require significant investment and reorientation to effectively manage CVDs.
Evidence from 18 countries has shown that hypertension programmes can be implemented efficiently and cost-effectively at the primary care level which will ultimately result in reduced coronary heart disease and stroke. Patients with cardiovascular disease should have access to appropriate technology and medication. Basic medicines that should be available include:
- . aspirin;
- . beta-blockers;
- . angiotensin-converting enzyme inhibitors;
- . statins.
An acute event such as a heart attack or stroke should be promptly managed.
Sometimes, surgical operations are required to treat CVDs. They include:
- . coronary artery bypass;
- . balloon angioplasty (where a small balloon-like device is threaded through an artery to open the blockage);
- . valve repair and replacement;
- . heart transplantation;
- . artificial heart operations.
Furthermore, healthcare professionals use medical devices such as pacemakers, prosthetic valves, and closure patches to treat specific cardiovascular conditions.Such devices include pacemakers, prosthetic valves, and patches for closing holes in the heart.
Research Peptides
Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans…
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma…
Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin-promoting peptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)…
Cagrilintide is an investigational long-acting acylated amylin analogue acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist…
Linaclotide is a potent and selective guanylate cyclase-C agonist developed for treatment of IBS-C and chronic constipation…
